Regulations of Free Fatty Acids and Diabetic Parameters in Drug Na ïve Subjects with Type 2 Diabetes Treated with Canagliflozin Monotherapy
The objective of this study is to investigate the regulations of FFA with
canagliflozin in relation to metabolic parameters. Drug naïve subjects
with T2DM were administered 50–100 mg/day canagliflozin
monotherapy (n=70) for 3 months. Significant correlations between the
changes of (Δ) FFA and Δadipo-IR (R=0.496), but no
correlations between ΔFFA and ΔHOMA-R were observed. The
subjects were divided into three groups with similar numbers according to
Δ FFA: group A: highest tertile: (ΔFFA=38.7%,
n=23); group B: intermediate tertile: (ΔFFA=2%,
n=23); group C: lowest tertile:
(ΔFFA=−36%, n=24). Metabolic parameters
were compared between group A and group C. At baseline, FFA was higher in group
C than group A (p<0.002). Greater degrees of HbA1c reduction and
increases of insulin were observed in group C than group A (both
p<0.05). In group A, significant reductions of BMI
(−2.6%) and HOMA-R (−30%) were seen. In group C,
significant reductions of non-HDL-C (−6.2%), UA
(−7.6%) or adipo-IR (−28.7%), and increases of
HOMA-B (+85.6%) were observed. Taken together, 1) certain
population treated with canagliflozin showed decreased FFA. 2) beta-cell
function increased while atherogenic cholesterol, UA and adipo-IR decreased in
those with reduced FFA. B...
Source: Drug Research - Category: Drugs & Pharmacology Authors: Kutoh, Eiji Kuto, Alexandra N. Wada, Askuka Kurihara, Rumi Kojima, Rina Tags: Original Article Source Type: research
More News: Canagliflozin | Cholesterol | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Insulin | Invokana | Study